Tfc Financial Management Immuno Gen, Inc. Transaction History

Tfc Financial Management

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 25, 2024	SELL	$12.46 - $29.95 $89,089 - $214,142	-7,150 Reduced 39.83%	10,800 $320,000
Q1 2022 May 04, 2022	BUY	$4.26 - $7.48 $11,715 - $20,570	2,750 Added 18.09%	17,950 $85,000
Q3 2020 Nov 12, 2020	BUY	$3.45 - $4.89 $52,440 - $74,328	15,200 New	15,200 $55,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Tfc Financial Management, based on Form 13F filings with the SEC.

Stay updated on Tfc Financial Management with notifications on news.